Related references
Note: Only part of the references are listed.
Article
Immunology
Jan Stephan F. Sanders et al.
Summary: The immune response to COVID-19 vaccination is inferior in kidney transplant recipients and to a lesser extent in patients on dialysis or with chronic kidney disease. The antibody levels and T-cell responses significantly decrease after 6 months of vaccination, and neutralization of the Omicron variant is barely detectable.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Alison Tarke et al.
Summary: T cell responses induced by different vaccine platforms cross-recognize early SARS-CoV-2 variants, while memory B cells and neutralizing antibodies show significant decreases. The majority of memory T cell responses are preserved against variants, with lower recognition of Omicron by memory B cells.
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.
Article
Biochemistry & Molecular Biology
Gian Luca Salvagno et al.
Summary: After healthcare workers received two doses of the Pfizer-BioNTech COVID-19 vaccine, serum levels of total anti-SARS-CoV-2 antibodies peaked 1 month after the second dose and gradually declined at 3 and 6 months. Despite the decline, antibody levels remained higher than the cut-off point, with no cases of seronegativization after 6 months. Baseline seropositive individuals experienced a more significant decline in antibodies, and younger subjects and women had consistently higher antibody levels at the 6-month follow-up.
JOURNAL OF MEDICAL BIOCHEMISTRY
(2022)
Article
Multidisciplinary Sciences
Jinyan Liu et al.
Summary: This study demonstrates that cellular immunity induced by current SARS-CoV-2 vaccines is highly conserved to the Omicron spike protein. Individuals vaccinated with Ad26.COV2.S or BNT162b2 vaccines showed durable spike-specific CD8(+) and CD4(+) T cell responses that were cross-reactive to both the Delta and Omicron variants, including in central and effector memory cellular subpopulations.
Article
Medicine, General & Internal
Roos S. G. Sablerolles et al.
Summary: This study investigated the immunogenicity and reactogenicity of a homologous or heterologous booster in healthcare workers who had received a single-shot Ad26.COV2.S vaccine. The results showed that booster vaccinations increased the levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses compared to a single Ad26.COV2.S vaccination. Boosters containing mRNA-based vaccines induced significantly higher levels of binding antibodies than homologous boosters. The mRNA-1273 booster was the most immunogenic but had higher reactogenicity compared to the BNT162b2 and Ad26.COV2.S boosters. Local and systemic reactions were generally mild to moderate in the first 2 days after booster administration.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Jan-Stephan F. Sanders et al.
Summary: In kidney patients, the immunogenicity, tolerability, and safety of COVID-19 vaccination vary. Kidney transplant recipients have a poor immune response, while patients with CKD G4/5 and those on dialysis have a comparable response to the control group. Dialysis patients and transplant recipients experience fewer adverse events after vaccination.
Article
Public, Environmental & Occupational Health
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Immunology
Corine H. GeurtsvanKessel et al.
Summary: This study demonstrates that vaccinated individuals retain T cell immunity to the SARS-CoV-2 Omicron variant, despite low levels of neutralizing antibodies. Booster vaccinations can partially restore cross-neutralization of the Omicron variant.
SCIENCE IMMUNOLOGY
(2022)
Article
Allergy
Leanne P. M. van Leeuwen et al.
Summary: This study evaluated the immune response of COVID-19 vaccines in patients with IEI. The results showed that COVID-19 vaccination was immunogenic in patients with mild antibody deficiencies and phagocyte defects, but had lower immunogenicity in patients with more severe IEI like CVID and combined B- and T-cell immunodeficiency. The presence of noninfectious complications and the use of immunosuppressive drugs negatively affected the antibody response in patients with CVID.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Hannes Lindahl et al.
Summary: The study describes the evolution of passive immunity to SARS-CoV-2 in commercial off-the-shelf Ig products used for IGRT during the pandemic, finding that while SARS-CoV-2 antibody concentrations in commercial Ig products increased over time, they remained inconsistently present and had reduced neutralizing capacity against the Omicron variant in batches with high concentrations of antibodies directed against the original virus strain.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Adrian M. Shields et al.
Summary: SARS-CoV-2 vaccines show reduced immunogenicity in patients with antibody deficiency, with evidence of vaccine breakthrough infections.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Marit J. van Gils et al.
Summary: This study compares the neutralization ability of different vaccines against various SARS-CoV-2 variants and finds that mRNA vaccines are superior to adenovirus vector-based vaccines in inducing neutralizing antibodies, both after initial vaccination and booster vaccination.
Review
Allergy
Jessica R. Durkee-Shock et al.
Summary: This article provides an update on the immunogenicity and safety of COVID-19 vaccines in patients with IEI. The study found that most patients with IEI showed antibody responses to COVID-19 vaccination, with stronger responses observed after mRNA vaccination. While neutralizing antibodies were detected in IEI patients, the levels were consistently lower than healthy controls. Risk factors for poor antibody responses included common variable immunodeficiency, autoimmune comorbidities, and rituximab use. T cell responses were detectable in most patients with IEI, but poorer responses were often found in patients with common variable immunodeficiency. Overall, COVID-19 vaccines were safe in patients with IEI and demonstrated immunogenicity in most individuals, especially with mRNA vaccinations.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
(2022)
Article
Immunology
Giulia Garzi et al.
Summary: This study shows that the use of antivirals and monoclonal antibodies in patients with Inborn Errors of Immunity can reduce the risk of hospitalization and severity of COVID-19. However, the emergence of new viral strains may diminish the effectiveness of monoclonal antibodies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Bibi Uhre Nielsen et al.
Summary: Multiple doses of SARS-CoV-2 vaccine in CVID patients appear to improve the antibody response, with antibody levels increasing after the third and fourth vaccine dose. However, the levels of anti-S-RBD from mAB treatment outperform those mounted after vaccination. IgRT products have varying concentrations of anti-S-RBD, but none of the products seem to affect the overall antibody levels.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Vera Goda et al.
Summary: This study evaluated the immune response of CVID patients receiving booster vaccination with BNT162b2 against SARS-CoV-2. The results showed that the vaccine can increase antibody levels and T cell response in CVID patients, but the response levels are still lower compared to healthy individuals.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Federica Pulvirenti et al.
Summary: After receiving the third booster dose of the mRNA vaccine, some patients with Common Variable Immune Deficiencies (CVID) may not produce specific antibodies against the spike protein of the virus. T cell abnormalities in these patients contribute to the absence of antibody production and result in a more complex disease phenotype.
Article
Immunology
Maria R. Farcet et al.
Summary: This study confirms the neutralizing effect of plasma-derived immunoglobulins from the US and European Union on the Omicron variant. Immunoglobulin preparations produced from plasma of COVID-19 recovered or vaccinated donors contain neutralizing antibodies against SARS-CoV-2.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Maya W. Keuning et al.
Summary: This study evaluated the feasibility of using saliva antibody assays for identifying SARS-CoV-2 humoral immunity in children. Results showed a slightly lower prevalence of S-specific IgG in saliva compared to serum, and differences in antibody levels were observed between girls and immunocompromised children.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Oon Tek Ng et al.
Summary: This cohort study assessed the effectiveness of booster vaccinations against severe COVID-19 and confirmed SARS-CoV-2 infection in Singapore during the Omicron wave. The study found that mRNA boosters provided protection against confirmed infection for 15 to 60 days, but the effectiveness waned after five months. mRNA boosters also showed high effectiveness against severe COVID-19. Three-dose inactivated SARS-CoV-2 vaccination provided greater protection than two-dose, but weaker protection compared to mRNA boosters.
Article
Immunology
Adrian M. Shields et al.
Summary: Third primary immunizations can enhance humoral immunity against SARS-CoV-2 in individuals with antibody deficiency.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Allergy
Isabelle Meyts et al.
Summary: The study shows that patients with IEI exhibit varied responses to SARS-CoV-2 infection, with some requiring hospitalization and even intensive care, and a non-negligible mortality rate. In comparison to the general population, younger IEI patients may face a higher risk of severe illness and mortality.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Philip J. M. Brouwer et al.
Summary: The study introduces a nanoparticle vaccine displaying multiple copies of the SARS-CoV-2 spike protein, which successfully induced potent antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high-dose challenge, showing promising potential as a candidate to curtail the COVID-19 pandemic.
Article
Allergy
Adrian M. Shields et al.
Summary: Patients with PID and symptomatic SID have higher morbidity and mortality risks from COVID-19 compared to the general population, requiring enhanced protective measures.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Letter
Medicine, General & Internal
Ai-ris Y. Collier et al.
Summary: The kinetics of immune response to Covid-19 vaccines were studied, showing varying peak levels and durations of response for different vaccines. However, the response levels correlating with protection have not been defined yet.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biology
Marloes Grobben et al.
Summary: Research shows that after SARS-CoV-2 infection and vaccination, humans produce cross-reactive antibodies against multiple coronaviruses, supporting the feasibility of developing a pan-coronavirus vaccine.
Article
Immunology
Donato Amodio et al.
Summary: The study analyzed the immune response following the BNT162b2 mRNA COVID-19 vaccine in immunocompromised patients compared to healthy controls. It found that some immunocompromised patients did not develop specific CD4+CD40L+ T cell responses, indicating the importance of evaluating T cell immune responses in this subpopulation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Allergy
David Hagin et al.
Summary: The study evaluated the humoral and cellular immune response to the COVID-19 vaccine in patients with IEI, finding that most patients were able to develop vaccine-specific antibody response and S-protein-specific cellular response, and no significant adverse events were reported during the vaccination process.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Allergy
Ottavia M. Delmonte et al.
Summary: The study evaluated antibody response and adverse events in IEI patients after COVID-19 vaccination, finding that vaccination is safe but immunogenicity is affected by certain therapies and gene defects. This data can guide counseling of IEI patients on preventing SARS-CoV-2 infection and the need for subsequent boosts.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Infectious Diseases
Marie Tre-Hardy et al.
Summary: A study on mRNA-1273 vaccine recipients showed a significant decrease in antibody levels after 6 months, especially in individuals who had not previously been vaccinated. In a supply-limited environment, it is recommended to prioritize the third dose for seronegative individuals prior to vaccination.
JOURNAL OF INFECTION
(2021)
Article
Microbiology
Maya W. Keuning et al.
Summary: Understanding the heterogeneity of SARS-CoV-2 antibodies in children is crucial for future public health and vaccine strategies. Our study demonstrates the additional value of saliva antibody detection next to detection of antibodies in serum, highlighting the heterogeneity of SARS-CoV-2 antibodies in terms of antigen specificity and differences between circulating and mucosal antibodies.
MICROBIOLOGY SPECTRUM
(2021)
Article
Immunology
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Article
Immunology
Oi-Wing Ng et al.
